Advertisement
Screener

AKEBIA THERAPEUTICS, INC. (AKBA) Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost

2.8 / 5 stars · 68/120 Roast Me

AKEBIA THERAPEUTICS, INC. Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost

AKEBIA THERAPEUTICS, INC. (AKBA) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost of $6.24 million as of 2024-12-31, per its 10-K filed 2025-03-13.

Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Tax Deferred Expense

us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost · last filed 2025-03-13

  • 2024-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $6.24M.
  • 2023-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $6.18M.
  • 2022-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $8.32M.
  • 2021-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $9.19M.
Period endDeferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost
2024-12-31$6.24M
10-K · filed 2025-03-13
2023-12-31$6.18M
10-K · filed 2025-03-13
2022-12-31$8.32M
10-K · filed 2024-03-14
2021-12-31$9.19M
10-K/A · filed 2023-08-28
2020-12-31$10.01M
10-K · filed 2022-03-01
2019-12-31$10.14M
10-K · filed 2021-02-25
2018-12-31$9.51M
10-K · filed 2020-03-12
2017-12-31$3.13M
10-K · filed 2019-03-26

Similar stocks

Stock NameCountryMarket CapPE Ratio
Lyell Immunopharma, Inc. (LYEL)United States$0.248B-1.32
Pyxis Oncology, Inc. (PYXS)United States$0.244B
Greenwich LifeSciences, Inc. (GLSI)United States$0.267B-15.02
Entrada Therapeutics, Inc. (TRDA)United States$0.243B-1.73
Cue Biopharma, Inc. (CUE)United States$0.243B-1.01
MACROGENICS INC (MGNX)United States$0.242B-20.11
Mereo BioPharma Group plc (MREO)$0.269B-9.41
Camp4 Therapeutics Corp (CAMP)United States$0.240B-2.12
Sionna Therapeutics, Inc. (SION)United States$0.236B-20.37
SIGA TECHNOLOGIES INC (SIGA)United States$0.234B-93.33